Rhythm Pharmaceuticals (RYTM) PT Lowered to $25 at Needham & Company on FDA Approval for BBS
Tweet Send to a Friend
Needham & Company analyst Alan Carr lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $25.00 (from $40.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
